Canada Pension Plan Investment Board Makes New Investment in Moderna, Inc. $MRNA

Canada Pension Plan Investment Board bought a new stake in Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 213,808 shares of the company’s stock, valued at approximately $14,973,000. Canada Pension Plan Investment Board owned 0.05% of Moderna as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of MRNA. MUFG Securities EMEA plc purchased a new position in shares of Moderna in the 2nd quarter worth $28,000. Allied Private Wealth LLC acquired a new position in Moderna in the second quarter valued at $30,000. Canton Hathaway LLC purchased a new stake in Moderna during the first quarter valued at about $31,000. EverSource Wealth Advisors LLC grew its position in Moderna by 148.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after acquiring an additional 801 shares during the period. Finally, Assetmark Inc. increased its stake in Moderna by 35.1% during the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after acquiring an additional 208 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 3.3%

NASDAQ:MRNA opened at $137.99 on Friday. The business’s 50-day moving average is $77.11 and its two-hundred day moving average is $59.73. The firm has a market capitalization of $55.09 billion, a PE ratio of -17.27 and a beta of 0.91. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $176.66. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.13) earnings per share. Research analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that their personalized mRNA melanoma vaccine, intismeran, combined with Keytruda, met the goals of a Phase 3 study involving 1,137 patients. The treatment reduced the risk of melanoma recurrence and distant spread versus Keytruda alone, strengthening the case for Moderna’s oncology pipeline and the commercial potential of the partnership. Reuters cancer vaccine breakthrough article
• Positive Sentiment: The U.S. FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, targeting the XFG subvariant. The approval preserves access to the seasonal COVID-19 vaccine market, though future demand remains an important uncertainty. Reuters FDA approval article
• Positive Sentiment: Argus upgraded Moderna from “Hold” to “Buy” and assigned a $180 price target, indicating additional potential upside based on the company’s oncology opportunity and recent clinical progress. Argus upgrade article
• Neutral Sentiment: Jim Cramer advised a viewer to hold Moderna after the stock’s sharp rally, reflecting continued optimism about the Phase 3 cancer-vaccine result but also caution following the run-up. Jim Cramer Moderna commentary
• Negative Sentiment: Moderna priced an upsized $2.6 billion offering of zero-coupon convertible senior notes due 2032, increased from the initially proposed $2.0 billion. Proceeds may fund oncology investments and debt repayment, but the larger financing raised concerns about future share dilution and explains much of the selling pressure. Moderna convertible notes offering
• Negative Sentiment: BioNTech’s decision to halt a mid-stage personalized mRNA colorectal-cancer vaccine trial after a review weakened sentiment across the mRNA oncology sector, raising broader questions about the difficulty of translating promising technology into successful cancer treatments. BioNTech colorectal cancer trial article

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MRNA. Citigroup raised their price objective on Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. JPMorgan Chase & Co. increased their target price on shares of Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. The Goldman Sachs Group raised their price target on shares of Moderna from $67.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, August 19th. Argus raised shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research report on Friday. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a $130.00 price objective on shares of Moderna in a research note on Wednesday, August 19th. Seven analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $80.53.

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the sale, the insider owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the transaction, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.80% of the stock is owned by company insiders.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.